Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00232297 | Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS | PHASE2 | COMPLETED | 153 | — | — | Jun 1, 2005 | Feb 1, 2007 | May 8, 2012 | 8 | United States, Belgium +6 |
| Name | Type | Description |
|---|---|---|
| SSR149744C | DRUG | - |
Inclusion Criteria: * Patient with an ICD implanted during the previous year for documented spontaneous life-threatening ventricular arrhythmia OR implanted with an ICD and with at least one appropriate ICD therapy (shock or anti-tachycardia pacing) for ventricular tachycardia or ventricular fibril...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Abbott Laboratories | ABT | 5 | — | Undisclosed |
| Medtronic Plc | MDT | 1 | — | Undisclosed |
| Boston Scientific Corporation | BSX | 1 | — | Undisclosed |
| HeartBeam, Inc. | BEAT | 1 | — | Undisclosed |